A Risk Model Developed Based on Homologous Recombination Deficiency Predicts Overall Survival in Patients With Lower Grade Glioma

• DOI: 10.3389/fgene.2022.919391
• Publication Date: 2022-07-01T07:04:17Z
• Authors: Hao Peng; Yibiao Wang; Pengcheng Wang; Chuixue Huang; Zhaohui Liu; Changwu Wu
• Keywords: 0301 basic medicine; 03 medical and health sciences; risk model; homologous recombination deficiency; lower grade glioma; immune cell infiltration; Genetics; prognosis; QH426-470; 3. Good health

The role of homologous recombination deficiency (HRD) in lower grade glioma (LGG) has not been elucidated, and accurate prognostic prediction is also important for the treatment management LGG. aim this study was to construct an HRD-based risk model explore immunological molecular characteristics model. HRD score threshold = 10 determined from 506 LGG samples Cancer Genome Atlas cohort using best cut-off value, patients with high scores had worse overall survival. A total 251 HRD-related genes were identified by analyzing differentially expressed genes, 182 which associated based on constructed univariate Cox regression, least absolute shrinkage selection operator stepwise divided into high- low-risk groups median score. High-risk significantly survival than patients. excellent predictive performance found be independent factor. value validated cohort. In addition, tumor mutation burden immune cell infiltration higher "hot" microenvironment, could benefit poly-ADP-ribose polymerase inhibitors checkpoint inhibitors. Overall, big data LGG, developed a This provides potential new targets future targeted therapies facilitates development individualized immunotherapy improve prognosis.